Jim Wassil - 02 Mar 2022 Form 4 Insider Report for Vaxcyte, Inc. (PCVX)

Role
Chief Operating Officer
Signature
/s/ Ron Metzger, Attorney-in-Fact
Issuer symbol
PCVX
Transactions as of
02 Mar 2022
Net transactions value
$0
Form type
4
Filing time
04 Mar 2022, 19:58:45 UTC
Previous filing
28 Feb 2022
Next filing
20 Apr 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCVX Common Stock Award $0 +25,000 +139% $0.000000 42,944 02 Mar 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCVX Stock Option (right to buy) Award $0 +100,000 $0.000000 100,000 02 Mar 2022 Common Stock 100,000 $24.79 Direct F2
transaction PCVX Stock Option (right to buy) Award $0 +150,000 $0.000000 150,000 02 Mar 2022 Common Stock 150,000 $24.79 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as to 25% of the shares subject to the award on September 2, 2022 and 12.5% of the shares every six months thereafter.
F2 12/48 of shares subject to the option vest on February 15, 2023, and 1/48 of the shares vest monthly thereafter.
F3 1/48 of shares subject to the option vest on April 2, 2022, and 1/48 of the shares vest monthly thereafter.